Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

References for PMC Articles for PubMed (Select 22513362)

1.

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.

Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, Mueller I, Savory WJ, Williams DH, Eyers PA.

ACS Chem Biol. 2010 Jun 18;5(6):563-76. doi: 10.1021/cb100053q.

PMID:
20426425
2.

Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.

Dodson CA, Kosmopoulou M, Richards MW, Atrash B, Bavetsias V, Blagg J, Bayliss R.

Biochem J. 2010 Mar 15;427(1):19-28. doi: 10.1042/BJ20091530. Erratum in: Biochem J. 2010;427(3):551.

PMID:
20067443
3.

Essential roles of mTOR/Akt pathway in Aurora-A cell transformation.

Taga M, Hirooka E, Ouchi T.

Int J Biol Sci. 2009 Jun 19;5(5):444-50.

4.

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M.

Cancer Cell. 2009 Jan 6;15(1):67-78. doi: 10.1016/j.ccr.2008.12.005.

5.

The aurora kinase A regulates GSK-3beta in gastric cancer cells.

Dar AA, Belkhiri A, El-Rifai W.

Oncogene. 2009 Feb 12;28(6):866-75. doi: 10.1038/onc.2008.434. Epub 2008 Dec 8.

6.

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.

Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, Balmain A.

Science. 2008 Sep 12;321(5895):1499-502. doi: 10.1126/science.1162981.

7.

The Fbxw7/hCdc4 tumor suppressor in human cancer.

Tan Y, Sangfelt O, Spruck C.

Cancer Lett. 2008 Nov 18;271(1):1-12. doi: 10.1016/j.canlet.2008.04.036. Epub 2008 Jun 9. Review.

PMID:
18541364
8.

Tenets of PTEN tumor suppression.

Salmena L, Carracedo A, Pandolfi PP.

Cell. 2008 May 2;133(3):403-14. doi: 10.1016/j.cell.2008.04.013.

9.

Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy.

Lassmann S, Shen Y, Jütting U, Wiehle P, Walch A, Gitsch G, Hasenburg A, Werner M.

Clin Cancer Res. 2007 Jul 15;13(14):4083-91.

10.

High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers.

Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A.

Cancer Biol Ther. 2007 Apr;6(4):525-33.

PMID:
17457043
11.

Roles of Aurora kinases in mitosis and tumorigenesis.

Fu J, Bian M, Jiang Q, Zhang C.

Mol Cancer Res. 2007 Jan;5(1):1-10. Review.

12.

Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.

Yang H, He L, Kruk P, Nicosia SV, Cheng JQ.

Int J Cancer. 2006 Nov 15;119(10):2304-12.

PMID:
16894566
13.

Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.

Fujii Y, Yada M, Nishiyama M, Kamura T, Takahashi H, Tsunematsu R, Susaki E, Nakagawa T, Matsumoto A, Nakayama KI.

Cancer Sci. 2006 Aug;97(8):729-36.

PMID:
16863506
14.

The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.

Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr.

Cancer Cell. 2005 Jul;8(1):25-33.

15.

Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A.

Nature. 2004 Dec 9;432(7018):775-9.

PMID:
15592418
16.

Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models.

Zhang D, Hirota T, Marumoto T, Shimizu M, Kunitoku N, Sasayama T, Arima Y, Feng L, Suzuki M, Takeya M, Saya H.

Oncogene. 2004 Nov 18;23(54):8720-30.

PMID:
15480417
17.

Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression.

Mao JH, To MD, Perez-Losada J, Wu D, Del Rosario R, Balmain A.

Genes Dev. 2004 Aug 1;18(15):1800-5.

18.

Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI.

EMBO J. 2004 May 19;23(10):2116-25. Epub 2004 Apr 22.

19.

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM.

Nat Med. 2004 Mar;10(3):262-7. Epub 2004 Feb 22. Erratum in: Nat Med. 2007 Apr;13(4):511.

20.

Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein.

Tetzlaff MT, Yu W, Li M, Zhang P, Finegold M, Mahon K, Harper JW, Schwartz RJ, Elledge SJ.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3338-45. Epub 2004 Feb 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk